MDNAF · Medicenna Therapeutics Corp.
Market Cap
$27.41M
Shares
92.30M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.28
Open$0.27
Day$0.26–0.28
52W close$0.24–1.19
Avg vol 30d43K
Short int511K · 0.6% float · 6.8d
Short vol74%
DataJan 2020–Sep 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-62.2%
Trailing year
Short interest
0.6%
Latest settlement · 6.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−42%
below
Price vs 50-day avg
−3%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−7%
trailing
6-month return
−40%
trailing
YTD return
−59%
this year
Relative strength
−58%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.55% of float · ▲ +4.1% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 3-yr low, contrarian setup
Squeeze score
56
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−80%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−42%
Bearish
Price vs 50-day avg
−3%
Neutral
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.55% of float · ▲ +4.1% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 4%
Range high $1
vs 200-day avg -42%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MDNAF
this stock
Medicenna Therapeutics Corp.
|
$27.41M | -58.8% | — | — | 0.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.06B | +13.9% | +46.2% | 29.9 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.83B | +2.3% | +20.8% | 19.2 | 2.5% |
|
ARGX
Argenx SE
|
$60.93B | +18.4% | — | — | 2.0% |
|
CSLLY
Csl Ltd
|
$59.64B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
1
- % held
- 0.2%
- Net QoQ
- +50.0K sh
- Top holder
- ORG Partners LLC
Held
Float
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MDNAF | -7.9% | -7.1% | -39.9% | -18.7% | -58.8% |
| SPY | +0.6% | -0.8% | +18.2% | -0.6% | +11.8% |
| vs SPY | -8.6% | -6.2% | -58.1% | -18.1% | -70.6% |